ob/ob Mouse Model of Obesity and Diabetes

Discover how Melior’s unique phenotypic screening platforms can uncover the untapped value of your candidate therapeutic

Type II diabetes is characterized by high blood glucose levels, insulin resistance, ß-cell loss, as well as a predisposition towards obesity and dyslipidemia. While there are many animal models of type II diabetes that demonstrate impaired glucose challenge (see OGTT mouse model), the ob/ob mice model is a well-accepted model of type II diabetes that recapitulates many aspects of type II diabetes in humans.

Ob/ob mice express mutations in the leptin gene that lead to obesity. These mice display progressive food intake, insulin resistance and moderately increased blood glucose levels. This strain can be used to model prediabetes, and early phases of diabetes and obesity. Melior uses this model to evaluate test compound’s ability to treat the above-mentioned conditions.

The graph illustrates the difference in response to a blood glucose challenge in ob/ob mice treated with vehicle or rosiglitazone – an insulin sensitizer and antidiabetic drug. Ob/ob mice administered rosiglitazone show significantly lower blood glucose across time relative to vehicle treated mice. Data are mean ± SEM; * p<0.05, **p<0.01 compared to vehicle (N=4-7).

The ob/ob mouse model may be used in an acute setting but is more typically used in a chronic setting to evaluate a compound’s cumulative action over several weeks of treatment. The variability if reasonably low such that good statistically significant effects are seen with validating compounds with group sizes of about 8 animals.

Interested in running a Diabetes Model study?

If you are interested in learning more about the ob/ob Mouse Model of Type II Diabetes, please contact us to start the conversation today!

Discuss your project with us

We chose Melior Discovery because they were responsive and cost effective. We are staying with them as a chosen scientific partner because of their thoughtful scientific input to experimental design and attention to detail. Their expertise and flexibility allowed us to quickly adapt the study design and evaluate additional outcome measures to pursue unexpected activity.
Sridharan Rajamani, Ph.D., Senior Research Scientist
Gilead Sciences
I have been working with Melior on a number of projects over the course of a few years now. They have been a great partner throughout this time. The scientists whom I have worked with have been great problem-solvers and were customer focused
Jay Lichter
Avalon Ventures
[We] have been impressed with [Melior’s] ability to rapidly and effectively evaluate compounds in animal models…as we strive to identify compounds to ameliorate the devastating symptoms of Rett,
Monica Coenraads, Executive Director
Rett Syndrome Research Trust
Melior is more than just a service company. Their experienced staff guided us in our drug development efforts. We consider Melior an extension of our own research team.
Josh Schultz
Carolus Therapeutics
Addex Therapeutics has been collaborating with Melior Discovery for more than a year. The studies performed at Melior are always carefully planned and skilfully executed while the progress of the project is well-tracked and communicated to the customer. On several occasions, when testing our compounds in a new in vivo assay, we relied on Melior's scientists in their guidance and advice. We have been particularly pleased with a series of experiments involving assessment of compounds' profiles in the rat sleep/wake EEG. This approach, that has a translational relevance, offered a sensitive measure of a compound's efficacy and side-effects
Mikhail Kalinichev, Ph.D., Associate Research Director
Addex Therapeutics
Having worked with Melior quite extensively over the past several years, we find the team to be highly knowledgeable, responsive and adaptable to our needs. The overall process has been highly efficient and we are impressed by the quality of their reports
Christopher Prior, Ph.D., CEO,
PhaseBio Pharmaceuticals Inc.
…to evaluate our lead compound in an EEG-based sleep wake model. Melior’s very experienced team provided valuable insights and recommendations on study design, analysis and interpretation of the data. As a virtual company, Prexa relied on Melior to become an extension of our knowledge team and they met all our expectations
Pat Baskin and Ev Graham
Prexa Pharmaceuticals
State of-the-art Preclinical Pharmacology
Melior provided State-of-the-art Preclinical Pharmacology Support for a period of nearly a year where a series of in vivo studies were completed on a weekly basis. The staff was extremely user-friendly and the operational processes were excellent. I can recommend Melior without reservation.
Richard DiMarchi, PhD
Cox Professor of Chemistry & Gil Chair in Biomolecular Sciences Indiana University, Department of Chemistry